102 related articles for article (PubMed ID: 20331457)
1. MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma.
Robertus JL; Kluiver J; Weggemans C; Harms G; Reijmers RM; Swart Y; Kok K; Rosati S; Schuuring E; van Imhoff G; Pals ST; Kluin P; van den Berg A
Br J Haematol; 2010 Jun; 149(6):896-9. PubMed ID: 20331457
[No Abstract] [Full Text] [Related]
2. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
[TBL] [Abstract][Full Text] [Related]
3. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma.
Metzler M; Wilda M; Busch K; Viehmann S; Borkhardt A
Genes Chromosomes Cancer; 2004 Feb; 39(2):167-9. PubMed ID: 14695998
[No Abstract] [Full Text] [Related]
4. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation.
Leucci E; Cocco M; Onnis A; De Falco G; van Cleef P; Bellan C; van Rijk A; Nyagol J; Byakika B; Lazzi S; Tosi P; van Krieken H; Leoncini L
J Pathol; 2008 Dec; 216(4):440-50. PubMed ID: 18802929
[TBL] [Abstract][Full Text] [Related]
5. Expression of P0- and P3-RNA from the normal and translocated c-myc allele in Burkitt's lymphoma cells.
Eick D; Polack A; Kofler E; Lenoir GM; Rickinson AB; Bornkamm GW
Oncogene; 1990 Sep; 5(9):1397-402. PubMed ID: 2216463
[TBL] [Abstract][Full Text] [Related]
6. Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs.
Van Vlierberghe P; De Weer A; Mestdagh P; Feys T; De Preter K; De Paepe P; Lambein K; Vandesompele J; Van Roy N; Verhasselt B; Poppe B; Speleman F
Br J Haematol; 2009 Dec; 147(5):686-90. PubMed ID: 19775296
[TBL] [Abstract][Full Text] [Related]
7. Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation.
De Falco G; Ambrosio MR; Fuligni F; Onnis A; Bellan C; Rocca BJ; Navari M; Etebari M; Mundo L; Gazaneo S; Facchetti F; Pileri SA; Leoncini L; Piccaluga PP
BMC Cancer; 2015 Oct; 15():668. PubMed ID: 26453442
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous involvement with Burkitt-like lymphoma.
Pettey AA; Walsh JS
Am J Dermatopathol; 2007 Apr; 29(2):184-6. PubMed ID: 17414444
[TBL] [Abstract][Full Text] [Related]
9. Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma.
Kluiver J; van den Berg A; de Jong D; Blokzijl T; Harms G; Bouwman E; Jacobs S; Poppema S; Kroesen BJ
Oncogene; 2007 May; 26(26):3769-76. PubMed ID: 17173072
[TBL] [Abstract][Full Text] [Related]
10. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
11. Advances in the understanding of MYC-induced lymphomagenesis.
Klapproth K; Wirth T
Br J Haematol; 2010 May; 149(4):484-97. PubMed ID: 20346013
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of inactivation of the normal c-myc gene locus in human Burkitt lymphoma cells.
Nishikura K; Murray JM
Oncogene; 1988 May; 2(5):493-8. PubMed ID: 3131718
[TBL] [Abstract][Full Text] [Related]
13. ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma.
Dzikiewicz-Krawczyk A; Kok K; Slezak-Prochazka I; Robertus JL; Bruining J; Tayari MM; Rutgers B; de Jong D; Koerts J; Seitz A; Li J; Tillema B; Guikema JE; Nolte IM; Diepstra A; Visser L; Kluiver J; van den Berg A
Leukemia; 2017 Jun; 31(6):1470-1473. PubMed ID: 28331227
[No Abstract] [Full Text] [Related]
14. Hidden gene amplifications in aggressive B-cell non-Hodgkin lymphomas detected by microarray-based comparative genomic hybridization.
Wessendorf S; Schwaenen C; Kohlhammer H; Kienle D; Wrobel G; Barth TF; Nessling M; Möller P; Döhner H; Lichter P; Bentz M
Oncogene; 2003 Mar; 22(9):1425-9. PubMed ID: 12618769
[TBL] [Abstract][Full Text] [Related]
15. Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma.
Kluiver J; Haralambieva E; de Jong D; Blokzijl T; Jacobs S; Kroesen BJ; Poppema S; van den Berg A
Genes Chromosomes Cancer; 2006 Feb; 45(2):147-53. PubMed ID: 16235244
[TBL] [Abstract][Full Text] [Related]
16. [c-myc gene].
Naoe T
Nihon Rinsho; 1990 Aug; 48(8):35-40. PubMed ID: 2255093
[No Abstract] [Full Text] [Related]
17. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
18. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
19. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement.
Nakamura N; Nakamine H; Tamaru J; Nakamura S; Yoshino T; Ohshima K; Abe M
Mod Pathol; 2002 Jul; 15(7):771-6. PubMed ID: 12118116
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs and cancer.
Cowland JB; Hother C; Grønbaek K
APMIS; 2007 Oct; 115(10):1090-106. PubMed ID: 18042145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
